Here's How Much a $1000 Investment in ResMed Made 10 Years Ago Would Be Worth Today

ResMed (RMD) is a leading designer, manufacturer and distributor of CPAP/VPAP devices, masks and cloud-connected platforms (AirSense10/11) with two operating segments: Sleep & Breathing Health (87.5% of FY2025 revenue) and Residential Care Software (~12.5% of FY2025), both up ~10% year-over-year. A $1,000 investment in January 2016 would be worth $4,790.66 as of January 15, 2026 (gain 379.07%, excludes dividends); the firm cites a modelled 6% revenue CAGR through FY2028, continued product innovation and SaaS expansion, but notes margin pressure from pricing headwinds in the US and Europe and competitive risks. Shares have rallied ~5.5% over the past four weeks and analysts raised FY2025 estimates twice in the last two months, supporting a constructive near-term outlook despite margin concerns.

Analysis

Market structure: ResMed (RMD) is positioned to win share in cloud-connected CPAP/VPAP and recurring mask resupply revenue, benefiting from aging demographics and higher recurring SaaS mix (Sleep & Breathing ~87.5%, Residential Care Software ~12.5%). Direct losers are lower‑tier device incumbents and commoditized Chinese OEMs if RMD sustains platform lock‑in; payers and large DME consolidators gain pricing leverage. Cross‑asset: sustained margin pressure would widen RMD equity volatility and could modestly widen high‑grade healthcare credit spreads (~10–30bp) if guidance weakens, while EUR/CNY moves affect manufacturing margins and reported revenue mix.

Risk assessment: Key tail risks are a large device recall/cyber breach, aggressive CMS reimbursement cuts, or a rapid entry of low‑cost Chinese substitutes—each could shave 200–400bps off gross margin and cut consensus CAGR below 3% vs modeled 6%. Near term (days–weeks) watch next quarterly EPS and margin commentary; medium term (1–4 quarters) is critical for resupply cadence and pricing trends; long term (into 2028–2030) success hinges on scaling SaaS margins and international pricing normalization. Hidden dependency: resupply growth is contingent on DME distribution economics and insurer acceptance, not just product launches.

Trade implications: Tactical long bias with risk management — build a 2–3% core long RMD position on up to 8–12% pullbacks or ahead of earnings only with hedges; consider 9–12 month 1:1 call spreads (buy 0–10% ITM, sell 20–30% OTM) to cap premium and leverage upside. Relative trade: long RMD vs short IHI (iShares U.S. Medical Devices ETF) to express idiosyncratic strength vs broader device weakness. For income/defensive holders, sell 30–60 day OTM covered calls to harvest 3–6% monthly yield while retaining upside.

Contrarian angles: Consensus may underprice downside margin risk but also underappreciate durable SaaS upside — if RMD converts 25–35% of device customers to subscription ARR, multiple expansion of 2–4 turns is plausible. The market could be underestimating regulatory/data‑privacy risks to cloud devices; conversely, pricing pressure could accelerate consolidation favoring RMD as scale advantage intensifies. Watch gross margin move >200bps and SaaS ARR growth acceleration >20% as decisive signals.

Key Decisions for Investors

• Establish a 2–3% long position in RMD (ResMed) on either a pullback of 8–12% or in stages over the next 30 days; set a protective stop at 12–15% below entry or buy a 3–6 month 7–10% OTM protective put capped at 1–2% of portfolio risk.
• Execute a 9–12 month call‑spread (bull call spread) on RMD: buy 0–10% ITM calls and sell 20–30% OTM calls sized to represent ~1.5–2% portfolio exposure to capture upside while limiting premium spent.
• Implement a relative‑value pair: go long RMD 2% vs short IHI 1.5% (size to net neutral beta) to isolate company‑specific execution; rebalance if spread narrows by 30% or if RMD reports a margin miss >200bps.
• If holding long-term, convert 30–50% of RMD position into a covered‑call income program: sell 30–60 day OTM calls to generate 3–6% monthly yield, and redeploy proceeds into healthcare SaaS names if margin guidance deteriorates by >150bps.
• Reduce exposure to commodity/low‑margin DME manufacturers by 50% within healthcare allocation if RMD reports sequential revenue growth <4% or gross margin contraction >200bps in the next two quarters; re-enter if SaaS ARR growth >20% y/y or margins recover.